10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 May 2003. Related: Conference reports.
CROI 10 (Retrovirus) 2003
Pharmacokinetic papers from 10th CROI
1 May 2003. Related: Conference reports, PK and drug interactions.
Pediatric studies from 10th CROI
1 May 2003. Related: Conference reports, Women's health, Pregnancy, Paediatric care.
10th Conference on Retroviruses and Opportunistic Infections (CROI), 10-14 February 2003, Boston, USA
1 April 2003. Related: Conference reports.
Pipeline compounds in Phase 2/3 Studies
1 April 2003. Related: Conference reports, Antiretrovirals.
96-week results show tenofovir-including regimen has side-effect advantages over d4T regimen in treatment naïve patients
1 April 2003. Related: Conference reports, Antiretrovirals.
2NN results – nevirapine and efavirenz in prospective randomised head-to-head study
1 April 2003. Related: Conference reports, Antiretrovirals.
NIH/NIAID study of generic drugs shows results consistent with stringent manufacturing standards
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment access, PK and drug interactions.
Treatment interruptions: cycles, pauses, are just plain stopping?
1 April 2003. Related: Conference reports, Antiretrovirals, Treatment strategies.
Conference has strong emphasis on women
1 April 2003. Related: Conference reports, Women's health, Lipodystrophy and metabolic complications, Cancer and HIV.
Tenofovir and renal tubular dysfunction
1 April 2003. Related: Conference reports, Side effects.
Approaches to treatment of lipodystrophy
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Surgery for buffalo hump shows variable results depending on method
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Other studies – nucleosides and switching to abacavir; importance of lipoatrophy and buffalo hump
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
HAART to HEART: cardiovascular risk in HIV
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Alendronate, vitamin D and calcium are safe and effective treatment for HIV-associated bone loss
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Bone loss and fat loss are closely related in HIV patients on HAART
1 April 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Low dose 200/100 IDV/RTV managed by TDM in substudy of co-infected patients
1 April 2003. Related: Conference reports, PK and drug interactions, Hepatitis coinfection.
12-week response predicts which HIV-HCV coinfected patients will not benefit from continued pegylated interferon plus ribavirin
1 April 2003. Related: Conference reports, Hepatitis coinfection.
Pegylated interferon associated with eye disorders
1 April 2003. Related: Conference reports, Side effects, Hepatitis coinfection.
Nevirapine resistance – the cautionary tales continue
1 April 2003. Related: Conference reports, Pregnancy, Drug resistance.